中国首例拉沙热病例报道

doi:10.19871/j.cnki.xfcrbzz.2024.04.001

新发传染病电子杂志 ›› 2024, Vol. 9 ›› Issue (4): 1-5.doi: 10.19871/j.cnki.xfcrbzz.2024.04.001

• 新病快递 • 下一篇

中国首例拉沙热病例报道

冉启惠¹, 陈红¹, 黄亮², 孟令彬³, 陈竹⁴, 任利红¹, 杜清¹, 张钉山¹, 李晨曦³, 郑永利¹

1.成都市公共卫生临床医疗中心重症医学科,四川成都 610066;
2.成都市公共卫生临床医疗中心科研教学部,四川成都 610066;
3.成都市公共卫生临床医疗中心放射科,四川成都 610066;
4.成都市公共卫生临床医疗中心药物临床试验机构,四川成都 610066

收稿日期:2024-08-12 出版日期:2024-08-31 发布日期:2024-10-10
通讯作者: 郑永利,Email：1303094612@qq.com
基金资助:
1.四川省医学青年创新科研课题计划（Q19068）; 2.成都市卫生健康委员会医学科研课题（2022264）

The first case of Lassa fever in China

Ran Qihui¹, Chen Hong¹, Huang Liang², Meng Lingbin³, Chen Zhu⁴, Ren Lihong¹, Du Qing¹, Zhang Dingshan¹, Li Chenxi³, Zheng Yongli¹

1. Department of Critical Care Medicine, Public Health Clinical Center of Chengdu, Sichuan Chengdu 610066, China;
2. Department of Science and Education Division, Public Health Clinical Center of Chengdu, Sichuan Chengdu 610066, China;
3. Department of Radiology, Public Health Clinical Center of Chengdu, Sichuan, Sichuan Chengdu 610066, China;
4. Drug Clinical Trial Institutions,Public Health Clinical Center of Chengdu, Sichuan Chengdu 610066, China

Received:2024-08-12 Online:2024-08-31 Published:2024-10-10

摘要/Abstract

摘要： 拉沙热（Lassa fever）是一种由拉沙病毒（Lassa virus, LASV）引起的发热性传染病。该疾病于1969年在尼日利亚首次被报告,后在西非地区流行。LASV主要通过大鼠的尿液或粪便传播给人类,也可能通过接触感染者的血液、粪便或其他身体分泌物在人与人之间传播。拉沙热常见症状包括发热、头痛、呕吐、腹痛和咳嗽。本文报道了中国首例确诊拉沙热病例,该病例发病前曾在西非几内亚工作,发病后LASV血清荧光定量PCR检测和IgG抗体检测均为阳性,确诊拉沙热。确诊后,患者接受了利巴韦林联合对症支持治疗,病情逐渐好转。本研究全面回顾了该病例的流行病学史、临床症状、诊断过程、治疗措施及转归,以提高医务人员对拉沙热的认识和防治水平。通过对本病例的深入分析,为未来类似病例的快速识别与有效应对提供科学依据,促进公共卫生体系对输入性传染病防控能力的提升。

关键词: 拉沙热, 临床症状, 流行病学, 诊断, 治疗, 预防

Abstract: Lassa fever is a febrile infectious disease caused by the Lassa virus (LASV). This disease was first reported in Nigeria in 1969 and subsequently became endemic in the West African region. LASV is mainly transmitted to humans through urine or feces of rats and may also be transmitted from person to person through contact with the blood, feces, or other bodily secretions of infected persons. Common symptoms of Lassa fever include fever, headache, vomiting, abdominal pain and cough. This article reports on the first confirmed case of Lassa fever in China, where the patient had been working in Guinea, West Africa, prior to the onset of the disease. After the onset, both the Lassa virus serum fluorescent quantitative PCR test and the IgG antibody test were positive, confirming the diagnosis of Lassa fever. Following the diagnosis, the patient received treatment with ribavirin in combination with symptomatic supportive therapy, which led to a gradual improvement in condition. The article provides a comprehensive review of the case's epidemiological history, clinical symptoms, diagnostic process, treatment measures, and outcome, with the hope of raising medical staff and vigilance about this infectious disease. Through an in-depth analysis of this case, the article summarizes the lessons learned and offers a scientific basis for the rapid identification and effective response to similar cases in the future, thereby enhancing the public health system's capacity to prevent and control the importation of infectious diseases.

Key words: Lassa fever, Clinical symptoms, Epidemiology, Diagnosis, Treatment, Prevention

中图分类号:

R512.8

冉启惠, 陈红, 黄亮, 孟令彬, 陈竹, 任利红, 杜清, 张钉山, 李晨曦, 郑永利. 中国首例拉沙热病例报道[J]. 新发传染病电子杂志, 2024, 9(4): 1-5.

Ran Qihui, Chen Hong, Huang Liang, Meng Lingbin, Chen Zhu, Ren Lihong, Du Qing, Zhang Dingshan, Li Chenxi, Zheng Yongli. The first case of Lassa fever in China[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(4): 1-5.

参考文献

[1] ILORI EA, FURUSE Y, IPADEOLA OB, et al.Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1-May 6, 2018[J]. Emerg Infect Dis, 2019, 25(6):1066-1074.
[2] FRAME JD, BALDWIN JM JR, GOCKE DJ, et al.Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings[J]. AM J Trop Med Hyg, 1970, 19(4):677.
[3] AJAYI NA, UKWAJA KN, IFEBUNANDU NA, et al.Lassa fever-full recovery without ribavarin treatment: a case report[J]. Afr Health Sci, 2014, 14(4):1074-1077.
[4] MONATH TP, NEWHOUSE VF, KEMP GE, et al.Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone[J]. Science, 1974, 185(4147):263-265.
[5] LECOMPTE E, FICHET-CALVET E, DAFFIS S, et al.Mastomys natalensis and Lassa Fever, West Africa[J]. Emerg Infect Dis, 2006, 12(12):1971-1974.
[6] BATY RS, ALBRAKATI A, FARAG MA, et al.Infection pattern, case fatality rate and spread of Lassa virus in Nigeria[J]. BMC Infect Dis, 2021, 2021(21):1-9.
[7] JETOH RW, MALIK S, SHOBAYO B, et al.Lassa fever cases in Liberia epidemiological characteristics: a retrospective analysis of surveillance data, 2019-2020[J]. Int J Infect Dis, 2022, 122: 767-774.
[8] BALOGUN OO, AKANDE OW, HAMER DH.Lassa Fever: An Evolving Emergency in West Africa[J]. AM J Trop Med HY, 2021,104(2):466-473.
[9] SAFRONETZ D, MIRE C, ROSENKE K, et al.A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses[J]. PLoS Negl Trop Dis, 2015, 9(4): e0003736.
[10] OKOROIWU HU, LÓPEZ-MUÑOZ F, POVEDANO-MONTERO FJ. Bibliometric analysis of global Lassa fever research (1970-2017): A 47-Year study[J]. BMC Infect Dis, 2018, 18(1):639.
[11] MERSON L, BOURNER J, JALLOH S, et al.Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design[J]. PLoS Negl Trop Dis, 2021, 15(9): e0009788.
[12] SOGOBA N, FELDMANN H, SAFRONETZ D.Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity[J]. Zoonoses Public HLTH, 2012, 59(2):43-47.
[13] ETHEL NC, PETER EC, BASIL CE.Clinical Presentations of Lassa Fever in Non-Endemic Parts of the World: A Systematic Review[J]. Int J Clin Med, 2022, 13(9):415-427.
[14] THAIRU Y, EGENTI N.Understanding Lassa fever and diversification of rodent vector in the tropics[J]. Int J Curr Med Res, 2015, 4: 372-378.
[15] 中华预防医学会感染性疾病防控分会,中华医学会感染病学分会. 肾综合征出血热防治专家共识[J]. 中国实用内科杂志, 2021, 41(10): 845-854.
[16] SIDDALL E, KHATRI M, RADHAKRISHNAN J.Capillary leak syndrome: etiologies, pathophysiology, and management[J]. Kidney Int, 2017, 92(1): 37-46.
[17] 赵新华, 高燕军, 赵亮, 等. 急性炎性脱髓鞘脑病52例临床与影像学分析[J]. 河北医学, 2010, 16(6):763-764.
[18] CLARK W, TANTI M, AZZAM I, et al.Unusual demyelinating disease in a patient with HIV infection[J]. J Neurovirol, 2024, 80(4):315.
[19] GHEUENS S, PIERONE G, PEETERS P, et al.Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression[J]. J Neurol Neurosurps, 2009, 81(3): 247-254.
[20] LARSON RA, DAI D, HOSACK VT, et al.Identification of a broad-spectrum arenavirus entry inhibitor[J]. J Virol, 2008, 82(21):10768-10775.
[21] FRANCESCHI L.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage[J]. Hepatology, 2000, 31(4):997-1004.
[22] KARASAWA T, SAITO T, UENO Y, et al.Metabolome Analysis of Erythrocytes from Patients with Chronic Hepatitis C Reveals the Etiology of Ribavirin-Induced Hemolysis[J]. Int J Med Sci, 2013, 10(11):1575-1577.
[23] 刘敏,曾琴,潘亮,等.聚乙二醇干扰素α-2b联合利巴韦林治疗HIV/HCV合并感染的回顾性研究[J/CD].新发传染病电子杂志,2021,6(1):31-34.
[24] SALAM AP, DUVIGNAUD A, JASPARD M, et al.Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing[J]. PLoS Negl Trop Dis, 2022, 16(3): e0010289.
[25] MCCORMICK JB, KING IJ, WEBB PA, et al.Lassa fever. Effective therapy with ribavirin[J]. N Engl J Med, 1986, 314(1):20-26
[26] EBERHARDT K A, MISCHLINGER J, JORDAN S, et al.Ribavirin for the Treatment of Lassa Fever: A Systematic Review and Meta-Analysis[J]. Int J Infect Dis, 2019, 87:15-20.
[27] CHENG, HY, FRENCH, CE, SALAM, AP, et al.Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1[J]. Emerg Infect Dis, 2022, 28(8): 1559-1568.

中国首例拉沙热病例报道

The first case of Lassa fever in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	安永辉, 杨萱, 孙燕. 艾博韦泰联合多替拉韦治疗HIV感染/AIDS多重耐药1例报道[J]. 新发传染病电子杂志, 2024, 9(4): 57-60.
[2]	中华医学会感染病学分会艾滋病学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南（2024版）[J]. 新发传染病电子杂志, 2024, 9(4): 68-94.
[3]	武文艳, 关育红, 刘晶哲. 重新肆虐的百日咳给临床诊治带来新挑战[J]. 新发传染病电子杂志, 2024, 9(3): 1-4.
[4]	梅金周, 王云霞, 张梅娟, 桂静, 郑娟娟, 黄佩佩, 陈文胜, 郭艳芳. 全基因组测序技术在耐药肺结核诊断中的应用性评价[J]. 新发传染病电子杂志, 2024, 9(3): 16-20.
[5]	古晓利, 潘秋合, 陈建波, 郭青. 双能量CT增强与磁共振弹性成像联合诊断慢性乙型肝炎肝纤维化的临床价值[J]. 新发传染病电子杂志, 2024, 9(3): 56-60.
[6]	蔡川, 熊勋波, 杨红军. 散发型克-雅病1例并文献复习[J]. 新发传染病电子杂志, 2024, 9(3): 65-68.
[7]	滑少为, 赵子今, 赵萌, 申辛欣, 冯志山. 肠杆菌目细菌碳青霉烯酶检测的研究进展[J]. 新发传染病电子杂志, 2024, 9(3): 78-85.
[8]	胡玲利, 莫丹, 李康花, 张丽辉, 汪明明, 罗梦婷, 陈冲, 张志云, 袁素娥. 人工肝支持系统相关血源性病原体感染预防与控制专家共识[J]. 新发传染病电子杂志, 2024, 9(3): 98-104.
[9]	张银文, 曹新超, 谢荣景. 胸腔积液外泌体miR-506-3p联合腺苷脱氨酶检测在结核性胸膜炎的早期诊断及预后评估中的价值[J]. 新发传染病电子杂志, 2024, 9(2): 18-23.
[10]	王启征, 赵宇, 盛琪. 神经梅毒的诊疗进展[J]. 新发传染病电子杂志, 2024, 9(2): 79-83.
[11]	刘晶哲, 宋敏, 陆普选. 《耐药肺结核影像学诊断专家共识》解读[J]. 新发传染病电子杂志, 2024, 9(2): 99-103.
[12]	曹宪振, 马杰彦, 胡亮, 李高驰, 刘维强. 2108例儿童呼吸道病原体感染的流行病学特征[J]. 新发传染病电子杂志, 2024, 9(1): 12-16.
[13]	熊艳美, 李同心, 杨松, 孙楠楠. 重症结核合并肺栓塞1例并文献复习[J]. 新发传染病电子杂志, 2024, 9(1): 47-50.
[14]	姚伟明, 王福祥, 卢洪洲. 尼帕病毒的最新研究进展[J]. 新发传染病电子杂志, 2024, 9(1): 60-66.
[15]	汪成, 唐湘熠, 林子洵, 李倩, 卢洪洲. 猴痘合并HIV感染疾病特征的研究进展[J]. 新发传染病电子杂志, 2024, 9(1): 67-72.